Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis

P. Ryan, A. McBride, D. Ray, S. Pulgar, R. A. Ramirez, E. Elquza, J. P. Favaro, G. Dranitsaris

Research output: Contribution to journalArticle

Abstract

Background: Lanreotide and octreotide acetate suspension for injectable (LAR) are both recommended for clinical use in patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors. However, each agent possesses unique attributes in terms of their drug-delivery characteristics. The study objective was to compare overall drug-delivery efficiency between lanreotide and octreotide LAR in gastroenteropancreatic neuroendocrine tumor patients. Methods: This study employed an observational time and motion design among patients treated with lanreotide or octreotide LAR across five US cancer centers. Baseline patient data collection included age, disease grade and duration, prior therapies and performance status. Drug-delivery time (drug preparation and administration), total patient time and resource use data were collected for gastroenteropancreatic neuroendocrine tumors receiving lanreotide (n = 22) or octreotide LAR (n = 22). Following each administration, qualitative data on the drug-delivery experience was collected from patients and nurses. Results: Lanreotide was associated with a significant reduction in mean delivery time (2.5 min; 95% CI:2.0 to 3.1) compared to octreotide LAR (6.2 min; 95%CI: 4.4 to 7.9; p = 0.004). The mean total patient time for lanreotide and octreotide LAR was comparable between groups (32.1 vs. 36.6 minutes; p = 0.97). Nurses reported increased concerns with octreotide LAR related to needle clogging (p = 0.034) and device failures (p = 0.057). Overall, lanreotide had a median satisfaction score of 5.0 compared to a score of 4.0 with octreotide LAR (p = 0.03). Conclusions: Lanreotide was associated with significant reductions in drug-delivery time compared to octreotide LAR, which contributed to an improvement in overall healthcare efficiency. Trial registration: clinicaltrials.gov Identifier: NCT03017690.

Original languageEnglish (US)
Pages (from-to)1425-1433
Number of pages9
JournalJournal of Oncology Pharmacy Practice
Volume25
Issue number6
DOIs
StatePublished - Sep 1 2019
Externally publishedYes

Fingerprint

Octreotide
Pharmaceutical Preparations
Nurses
Equipment Failure
lanreotide
Gastro-enteropancreatic neuroendocrine tumor
Drug Compounding
Needles
Observational Studies
Suspensions
Delivery of Health Care
Injections

Keywords

  • cost
  • Lanreotide
  • neuroendocrine tumors
  • octreotide
  • time and motion

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors : An observational time and motion analysis. / Ryan, P.; McBride, A.; Ray, D.; Pulgar, S.; Ramirez, R. A.; Elquza, E.; Favaro, J. P.; Dranitsaris, G.

In: Journal of Oncology Pharmacy Practice, Vol. 25, No. 6, 01.09.2019, p. 1425-1433.

Research output: Contribution to journalArticle

Ryan, P. ; McBride, A. ; Ray, D. ; Pulgar, S. ; Ramirez, R. A. ; Elquza, E. ; Favaro, J. P. ; Dranitsaris, G. / Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors : An observational time and motion analysis. In: Journal of Oncology Pharmacy Practice. 2019 ; Vol. 25, No. 6. pp. 1425-1433.
@article{208df3e95546400f8f36c5f190a4cb20,
title = "Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis",
abstract = "Background: Lanreotide and octreotide acetate suspension for injectable (LAR) are both recommended for clinical use in patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors. However, each agent possesses unique attributes in terms of their drug-delivery characteristics. The study objective was to compare overall drug-delivery efficiency between lanreotide and octreotide LAR in gastroenteropancreatic neuroendocrine tumor patients. Methods: This study employed an observational time and motion design among patients treated with lanreotide or octreotide LAR across five US cancer centers. Baseline patient data collection included age, disease grade and duration, prior therapies and performance status. Drug-delivery time (drug preparation and administration), total patient time and resource use data were collected for gastroenteropancreatic neuroendocrine tumors receiving lanreotide (n = 22) or octreotide LAR (n = 22). Following each administration, qualitative data on the drug-delivery experience was collected from patients and nurses. Results: Lanreotide was associated with a significant reduction in mean delivery time (2.5 min; 95{\%} CI:2.0 to 3.1) compared to octreotide LAR (6.2 min; 95{\%}CI: 4.4 to 7.9; p = 0.004). The mean total patient time for lanreotide and octreotide LAR was comparable between groups (32.1 vs. 36.6 minutes; p = 0.97). Nurses reported increased concerns with octreotide LAR related to needle clogging (p = 0.034) and device failures (p = 0.057). Overall, lanreotide had a median satisfaction score of 5.0 compared to a score of 4.0 with octreotide LAR (p = 0.03). Conclusions: Lanreotide was associated with significant reductions in drug-delivery time compared to octreotide LAR, which contributed to an improvement in overall healthcare efficiency. Trial registration: clinicaltrials.gov Identifier: NCT03017690.",
keywords = "cost, Lanreotide, neuroendocrine tumors, octreotide, time and motion",
author = "P. Ryan and A. McBride and D. Ray and S. Pulgar and Ramirez, {R. A.} and E. Elquza and Favaro, {J. P.} and G. Dranitsaris",
year = "2019",
month = "9",
day = "1",
doi = "10.1177/1078155219839458",
language = "English (US)",
volume = "25",
pages = "1425--1433",
journal = "Journal of Oncology Pharmacy Practice",
issn = "1078-1552",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors

T2 - An observational time and motion analysis

AU - Ryan, P.

AU - McBride, A.

AU - Ray, D.

AU - Pulgar, S.

AU - Ramirez, R. A.

AU - Elquza, E.

AU - Favaro, J. P.

AU - Dranitsaris, G.

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Background: Lanreotide and octreotide acetate suspension for injectable (LAR) are both recommended for clinical use in patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors. However, each agent possesses unique attributes in terms of their drug-delivery characteristics. The study objective was to compare overall drug-delivery efficiency between lanreotide and octreotide LAR in gastroenteropancreatic neuroendocrine tumor patients. Methods: This study employed an observational time and motion design among patients treated with lanreotide or octreotide LAR across five US cancer centers. Baseline patient data collection included age, disease grade and duration, prior therapies and performance status. Drug-delivery time (drug preparation and administration), total patient time and resource use data were collected for gastroenteropancreatic neuroendocrine tumors receiving lanreotide (n = 22) or octreotide LAR (n = 22). Following each administration, qualitative data on the drug-delivery experience was collected from patients and nurses. Results: Lanreotide was associated with a significant reduction in mean delivery time (2.5 min; 95% CI:2.0 to 3.1) compared to octreotide LAR (6.2 min; 95%CI: 4.4 to 7.9; p = 0.004). The mean total patient time for lanreotide and octreotide LAR was comparable between groups (32.1 vs. 36.6 minutes; p = 0.97). Nurses reported increased concerns with octreotide LAR related to needle clogging (p = 0.034) and device failures (p = 0.057). Overall, lanreotide had a median satisfaction score of 5.0 compared to a score of 4.0 with octreotide LAR (p = 0.03). Conclusions: Lanreotide was associated with significant reductions in drug-delivery time compared to octreotide LAR, which contributed to an improvement in overall healthcare efficiency. Trial registration: clinicaltrials.gov Identifier: NCT03017690.

AB - Background: Lanreotide and octreotide acetate suspension for injectable (LAR) are both recommended for clinical use in patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors. However, each agent possesses unique attributes in terms of their drug-delivery characteristics. The study objective was to compare overall drug-delivery efficiency between lanreotide and octreotide LAR in gastroenteropancreatic neuroendocrine tumor patients. Methods: This study employed an observational time and motion design among patients treated with lanreotide or octreotide LAR across five US cancer centers. Baseline patient data collection included age, disease grade and duration, prior therapies and performance status. Drug-delivery time (drug preparation and administration), total patient time and resource use data were collected for gastroenteropancreatic neuroendocrine tumors receiving lanreotide (n = 22) or octreotide LAR (n = 22). Following each administration, qualitative data on the drug-delivery experience was collected from patients and nurses. Results: Lanreotide was associated with a significant reduction in mean delivery time (2.5 min; 95% CI:2.0 to 3.1) compared to octreotide LAR (6.2 min; 95%CI: 4.4 to 7.9; p = 0.004). The mean total patient time for lanreotide and octreotide LAR was comparable between groups (32.1 vs. 36.6 minutes; p = 0.97). Nurses reported increased concerns with octreotide LAR related to needle clogging (p = 0.034) and device failures (p = 0.057). Overall, lanreotide had a median satisfaction score of 5.0 compared to a score of 4.0 with octreotide LAR (p = 0.03). Conclusions: Lanreotide was associated with significant reductions in drug-delivery time compared to octreotide LAR, which contributed to an improvement in overall healthcare efficiency. Trial registration: clinicaltrials.gov Identifier: NCT03017690.

KW - cost

KW - Lanreotide

KW - neuroendocrine tumors

KW - octreotide

KW - time and motion

UR - http://www.scopus.com/inward/record.url?scp=85069521597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069521597&partnerID=8YFLogxK

U2 - 10.1177/1078155219839458

DO - 10.1177/1078155219839458

M3 - Article

C2 - 30924737

AN - SCOPUS:85069521597

VL - 25

SP - 1425

EP - 1433

JO - Journal of Oncology Pharmacy Practice

JF - Journal of Oncology Pharmacy Practice

SN - 1078-1552

IS - 6

ER -